a1 Harrisvaccines Inc., Ames, IA 50010, USA
a2 Immunobiology Program, Iowa State University, Ames, IA 50011, USA
a3 Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA
a4 Department of Animal Science, College of Agriculture, Iowa State University, Ames, IA 50011, USA
a5 Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Ames, IA, 50011, USA
Abstract
The alphavirus replicon technology has been utilized for many years to develop vaccines for both veterinary and human applications. Many developments have been made to the replicon platform recently, resulting in improved safety and efficacy of replicon particle (RP) vaccines. This review provides a broad overview of the replicon technology and safety features of the system and discusses the current literature on RP and replicon-based vaccines.
(Received November 23 2011)
(Accepted January 26 2012)
(Online publication March 21 2012)
Key Words:
Correspondence:
c1 Corresponding author: E-mail: rvanderveen@harrisvaccines.com